Prevention of Syncope Trial - POST


The goal of the trial is to evaluate treatment with the beta-blocker metoprolol for the prevention of vasovagal syncope.


Beta-blocker therapy with metoprolol will increase the time to the first recurrence of syncope compared with placebo.

Study Design

Patients Enrolled: 220
Mean Follow Up: 1 year

Patient Populations:

Positive tilt test with 3 syncopal spells preceding the tilt test


Seizures or other causes of syncope; important heart disease; a contraindication to or need for beta blockers; a permanent pacemaker; a major noncardiovascular disease; or previous use of beta blockers at a dose greater than the equivalent of metoprolol 25mg twice daily for the purpose of suppressing vasovagal syncope.

Primary Endpoints:

Time to first syncope recurrence

Secondary Endpoints:

Syncope frequency, presyncope, and quality of life

Drug/Procedures Used:

Patients will be randomized 1:1 to receive metoprolol or placebo, and followed for 1 year.

Principal Findings:

Not yet reported


Sheldon R, et al. Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope; rationale and study design. Europace. 2003 Jan;5(1):71-5

Keywords: Recurrence, Syncope, Vasovagal, Tilt-Table Test, Metoprolol

< Back to Listings